How should hydroxyurea be managed in a patient undergoing elective anesthesia, including timing of discontinuation, laboratory monitoring, and criteria for resuming the drug?

Hydroxyurea Management During Elective Anesthesia

Continue hydroxyurea through the perioperative period without interruption for elective surgery, as there is no evidence-based requirement to discontinue this medication before anesthesia.

Key Management Principles

The available evidence does not provide specific guidance on hydroxyurea discontinuation for elective procedures. The FDA labeling emphasizes monitoring for myelosuppression and requires weekly blood count monitoring during therapy 1, but contains no perioperative discontinuation recommendations. Similarly, the European LeukemiaNet guidelines for myeloproliferative neoplasms 2 focus on treatment response criteria and resistance definitions without addressing surgical interruption.

Preoperative Assessment

Laboratory Monitoring

• Obtain complete blood count within 1 week before surgery to assess baseline hematologic status 1
• Verify adequate cell counts:
  • Absolute neutrophil count ≥1.0 × 10⁹/L
  • Platelet count appropriate for surgical bleeding risk
  • Hemoglobin adequate for anticipated blood loss
• Severe anemia must be corrected before proceeding with elective surgery 1

Risk Stratification

The primary concern with hydroxyurea is myelosuppression 1, not drug-drug interactions with anesthetic agents. Evaluate:

• Current degree of cytopenia
• Bleeding risk of planned procedure
• Patient's underlying disease control

Perioperative Management Algorithm

For Patients with Normal Blood Counts

• Continue hydroxyurea without interruption
• No bridging therapy required
• Proceed with planned surgery

For Patients with Significant Cytopenia

If preoperative labs reveal:

• ANC <1.0 × 10⁹/L, OR
• Platelets <100 × 10⁹/L for moderate-high bleeding risk procedures, OR
• Hemoglobin <100 g/L 2

Then:

• Hold hydroxyurea temporarily
• Allow 7-14 days for count recovery (myelosuppression recovery is typically rapid when therapy is interrupted 1)
• Recheck counts before proceeding
• Consider postponing elective surgery if counts remain inadequate

Postoperative Resumption

Resume hydroxyurea on postoperative day 1 once:

• Patient tolerating oral intake
• No active bleeding complications
• Hemodynamic stability achieved

Monitoring After Resumption

• Obtain CBC within 1 week of restarting therapy 1
• Return to standard weekly monitoring schedule during dose titration
• Adjust dose if cytopenia develops

Critical Caveats

Avoid Common Pitfalls

1. Do not routinely discontinue hydroxyurea "just to be safe" - unnecessary interruption may worsen underlying disease control, particularly in sickle cell disease where stopping therapy increases vaso-occlusive crisis risk
2. Do not confuse hydroxyurea management with anticoagulant protocols - hydroxyurea is not a bleeding risk medication per se; the concern is procedural bleeding in the setting of drug-induced thrombocytopenia
3. Do not restart hydroxyurea if postoperative counts are suppressed - verify adequate recovery first

Special Considerations

• Renal impairment: Patients with creatinine clearance <60 mL/min require 50% dose reduction 1; ensure appropriate dosing when resuming postoperatively
• Sickle cell disease: Interrupting hydroxyurea increases acute complications risk 3, 4; minimize interruption duration
• Myeloproliferative disorders: Brief interruption is generally well-tolerated given slower disease kinetics 2

The absence of specific perioperative guidelines reflects hydroxyurea's favorable pharmacologic profile - it has no direct interaction with anesthetic agents and its primary toxicity (myelosuppression) is readily monitored and reversible 1.